Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1993

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Recent developments in contraception: 1.

AUTHORS

Szarewski A

SOURCE

PROFESSIONAL CARE OF MOTHER AND CHILD. 1993 Apr;3(4):90-1.

ABSTRACT

The greatest changes in contraception have occurred in hormonal contraceptive methods. Advantages of the new

combined oral contraceptives (OCs) with the new progestogens include no effect on high density lipoprotein

cholesterol or blood sugar and fewer androgenic side effects (e.g., acne and depression) than the older OCs. They

are suitable for women who smoke, are 30 years old or older, and have risk factors for cardiovascular disease. The

brand names of the new OCs are Marvelon (30 mcg ethinyl estradiol [EE] + 150 mcg desogestrel), Femodene and

Minulet (30 mcg EE + 75 mcg gestodene), Mercilon (20 mcg EE + 150 mcg desogestrel), and Cilest (35 mcg EE +

250 mcg norgestimate). Femodene and Minulet are suitable for women who need a new progestogen and have

problems with breakthrough bleeding when they use other brands. Mercilon causes few estrogenic side effects (e.g.,

breast tenderness and water retention) and rarely causes breakthrough bleeding. Cilest controls acne and hirsutism.

Progestogen only contraception is becoming more common. Advantages of the progestogen only pill (POP) are no

age limit (even among smokers) and can be used during lactation. Disadvantages include must be taken within 3

hours of the same time every day and menstrual irregularities. The UK Family Planning Association's new leaflet will

warn women who have missed POPs to take extra precautions for 7 days. The adverse press coverage on Depo-

Provera in the early 1980s explains why Depo-Provera use has been rather low. Depo-Provera is very effective (99.9%)

and poses few health risks. It does not increase the risk of breast, ovarian, or cervical cancers and has a 5-fold

protective effect against endometrial cancer. RU-486 combined with a prostaglandin pessary achieve early abortion

in 95% of cases. The guidelines for RU-486 and prostaglandin pessary use (e.g., requires several visits) limit its

availability. Side effects are linked to the pessary. The newly introduced female condom protects against AIDS. Its

acceptability is low, however. (PubHealth.info Document ID: CONT2T 4589-06)

PubHealth.info NOTE: The author(s) of this article titled, "Recent developments in contraception: 1.", is(are)

Szarewski A. The source of this article is "PROFESSIONAL CARE OF MOTHER AND CHILD. 1993 Apr;3(4):90-1.".

This article was published in 1993 in English language(s). (PubHealth.info® Document ID: CONT2T 4589-06. All

rights reserved with PubHealth.info) PIN: 9589

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.